{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:27:29Z","timestamp":1790807249663,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the United Fund of National Natural Science Foundation of China","award":["U2004110"],"award-info":[{"award-number":["U2004110"]}]},{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172129"],"award-info":[{"award-number":["82172129"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The central government guides local science and technology development funds","award":["Z20221343037"],"award-info":[{"award-number":["Z20221343037"]}]},{"name":"Medical Science and Technology Tackling Plan Provincial and Ministerial Major Projects of Henan Province","award":["SBGJ202101015)"],"award-info":[{"award-number":["SBGJ202101015)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In China\u2019s Henan province, 26 hospitals participated in a randomized controlled trial. We included patients with sepsis caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) susceptible to polymyxin B. The patients were randomly divided into a high-dose (HD) group or a low-dose (LD) group and received 150\u00a0mg loading dose, 75\u00a0mg every 12\u00a0h and 100\u00a0mg loading dose, 50\u00a0mg every 12\u00a0h, respectively. TDM was employed to determine if the dose of polymyxin B needs adjustment based on the area under the concentration\u2013time curve across 24\u00a0h at a steady state (ssAUC<jats:sub>0\u201324<\/jats:sub>) of 50\u2013100\u00a0mg\u00a0h\/L. The primary outcome was the 14-day clinical response, and the secondary outcomes included 28- and 14-day mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This trial included 311 patients, with 152 assigned to the HD group and 159 assigned to the LD group. Intention-to-treat analysis showed that the 14-day clinical response was non-significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.527): 95\/152 (62.5%) in the HD group and 95\/159 (59.7%) in the LD group. Kaplan\u2013Meier\u2019s 180-day survival curve showed survival advantage in the HD group than in the LD group (<jats:italic>p<\/jats:italic>\u2009=\u20090.037). More patients achieved the target ssAUC<jats:sub>0\u201324<\/jats:sub> in the HD than in the LD group (63.8% vs. 38.9%; <jats:italic>p<\/jats:italic>\u2009=\u20090.005) and in the septic shock subgroup compared to all subjects (HD group: 71.4% vs. 63.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.037; LD group: 58.3% vs. 38.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.0005). Also, the target AUC compliance was not correlated with clinical outcomes but with acute kidney injury (AKI) (<jats:italic>p<\/jats:italic>\u2009=\u20090.019). Adverse events did not differ between the HD and LD groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A fixed polymyxin B loading dose of 150\u00a0mg and a maintenance dose of 75\u00a0mg every 12\u00a0h was safe for patients with sepsis caused by CR-GNB and improves long-term survival. The increased AUC was associated with increased incidence of AKI, and TDM results were valued to prevent AKI.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Trial registration ClinicalTrials.gov: ChiCTR2100043208, Registration date: January 26, 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-023-04522-6","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T05:01:47Z","timestamp":1686632507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Shaohua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanzhang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"issue":"4","key":"4522_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMp1215093","volume":"368","author":"B Spellberg","year":"2013","unstructured":"Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med. 2013;368(4):299\u2013302. https:\/\/doi.org\/10.1056\/NEJMp1215093.","journal-title":"N Engl J Med"},{"issue":"3","key":"4522_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/s1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327. https:\/\/doi.org\/10.1016\/s1473-3099(17)30753-3.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4522_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, de Waele J, Daikos GL, Akova M, Harbarth S, et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521\u201347. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"4522_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/jac\/dkm357","volume":"60","author":"AP Zavascki","year":"2007","unstructured":"Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007;60(6):1206\u201315. https:\/\/doi.org\/10.1093\/jac\/dkm357.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4522_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1128\/CMR.00006-08","volume":"21","author":"D Landman","year":"2008","unstructured":"Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev. 2008;21(3):449\u201365. https:\/\/doi.org\/10.1128\/CMR.00006-08.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"4522_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10\u201339. https:\/\/doi.org\/10.1002\/phar.2209.","journal-title":"Pharmacotherapy"},{"key":"4522_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00208-17","author":"NJ Onufrak","year":"2017","unstructured":"Onufrak NJ, Rao GG, Forrest A, Pogue JM, Scheetz MH, Nation RL, Li J, Kaye KS. Critical need for clarity in polymyxin B dosing. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.00208-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"4522_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01493-17","author":"CJ Kubin","year":"2018","unstructured":"Kubin CJ, Nelson BC, Miglis C, Scheetz MH, Rhodes NJ, Avedissian SN, Cremers S, Yin MT. Population pharmacokinetics of intravenous polymyxin B from clinical samples. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.01493-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"4522_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00483-18","author":"EA Lakota","year":"2018","unstructured":"Lakota EA, Landersdorfer CB, Nation RL, Li J, Kaye KS, Rao GG, Forrest A. Personalizing polymyxin B dosing using an adaptive feedback control algorithm. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.00483-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"4522_CR10","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2147\/IDR.S357746","volume":"15","author":"J Qu","year":"2022","unstructured":"Qu J, Qi TT, Qu Q, Long WM, Chen Y, Luo Y, Wang Y. Polymyxin B-based regimens for patients infected with carbapenem-resistant gram-negative bacteria: clinical and microbiological efficacy, mortality, and safety. Infect Drug Resist. 2022;15:1205\u201318. https:\/\/doi.org\/10.2147\/IDR.S357746.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"4522_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12967-021-03111-x","volume":"19","author":"X Zhang","year":"2021","unstructured":"Zhang X, Qi S, Duan X, Han B, Zhang S, Liu S, Wang H, Zhang H, Sun T. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study. J Transl Med. 2021;19(1):431. https:\/\/doi.org\/10.1186\/s12967-021-03111-x.","journal-title":"J Transl Med"},{"issue":"4","key":"4522_CR12","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cid\/cit334","volume":"57","author":"AM Sandri","year":"2013","unstructured":"Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524\u201331. https:\/\/doi.org\/10.1093\/cid\/cit334.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4522_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.diagmicrobio.2018.01.005","volume":"91","author":"SS Richter","year":"2018","unstructured":"Richter SS, Karichu J, Otiso J, Van Heule H, Keller G, Cober E, Rojas LJ, Hujer AM, Hujer KM, Marshall S, et al. Evaluation of Sensititre Broth Microdilution Plate for determining the susceptibility of carbapenem-resistant Klebsiella pneumoniae to polymyxins. Diagn Microbiol Infect Dis. 2018;91(1):89\u201392. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.01.005.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"4522_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304\u201377. https:\/\/doi.org\/10.1007\/s00134-017-4683-6.","journal-title":"Intensive Care Med"},{"issue":"5","key":"4522_CR15","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/ftd.0000000000000754","volume":"42","author":"P Wang","year":"2020","unstructured":"Wang P, Zhang Q, Qin Z, Xing H, Xu M, Pei H, Yang J, Zhang X. A simple and robust liquid chromatography with tandem mass spectrometry analytical method for therapeutic drug monitoring of plasma and cerebrospinal fluid polymyxin B1 and B2. Ther Drug Monit. 2020;42(5):716\u201323. https:\/\/doi.org\/10.1097\/ftd.0000000000000754.","journal-title":"Ther Drug Monit"},{"key":"4522_CR16","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3389\/fphar.2020.00829","volume":"11","author":"P Wang","year":"2020","unstructured":"Wang P, Zhang Q, Zhu Z, Feng M, Sun T, Yang J, Zhang X. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections. Front Pharmacol. 2020;11:829. https:\/\/doi.org\/10.3389\/fphar.2020.00829.","journal-title":"Front Pharmacol"},{"issue":"10","key":"4522_CR17","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1086\/592577","volume":"47","author":"AP Zavascki","year":"2008","unstructured":"Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008;47(10):1298\u2013304. https:\/\/doi.org\/10.1086\/592577.","journal-title":"Clin Infect Dis"},{"key":"4522_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01337-16","author":"V Thamlikitkul","year":"2017","unstructured":"Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, Tam VH. Dosing and pharmacokinetics of polymyxin B in patients with renal insufficiency. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.01337-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4522_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391\u2013400. https:\/\/doi.org\/10.1016\/s1473-3099(18)30099-9.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"4522_CR20","doi-asserted-by":"publisher","first-page":"106599","DOI":"10.1016\/j.ijantimicag.2022.106599","volume":"60","author":"P Wang","year":"2022","unstructured":"Wang P, Xing H, Zhang F, Liu S, Lu Y, Zhang X, Yang J, Sun T. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration. Int J Antimicrob Agents. 2022;60(1):106599. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106599.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"4522_CR21","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-184. https:\/\/doi.org\/10.1159\/000339789.","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"4522_CR22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1111\/bcp.14576","volume":"87","author":"XB Yu","year":"2021","unstructured":"Yu XB, Jiao Z, Zhang CH, Dai Y, Zhou ZY, Han L, Wen X, Sheng CC, Lin GY, Pan JY. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions. Br J Clin Pharmacol. 2021;87(4):1869\u201377. https:\/\/doi.org\/10.1111\/bcp.14576.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"4522_CR23","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/jcpt.13711","volume":"47","author":"Q Ye","year":"2022","unstructured":"Ye Q, Wang Q, Chen W, Zhang R, Chen Z, Li P, Zhang X, Zhan Q, Wang C. The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation. J Clin Pharm Ther. 2022;47(10):1608\u201318. https:\/\/doi.org\/10.1111\/jcpt.13711.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"4522_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s13054-022-04195-7","volume":"26","author":"J Yang","year":"2022","unstructured":"Yang J, Liu S, Lu J, Sun T, Wang P, Zhang X. An area under the concentration-time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria. Crit Care. 2022;26(1):320. https:\/\/doi.org\/10.1186\/s13054-022-04195-7.","journal-title":"Crit Care"},{"issue":"11","key":"4522_CR25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, McIntyre L, Ostermann M, Prescott HC, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181\u2013247. https:\/\/doi.org\/10.1007\/s00134-021-06506-y.","journal-title":"Intensive Care Med"},{"issue":"9","key":"4522_CR26","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/jac\/dkq226","volume":"65","author":"RV Dudhani","year":"2010","unstructured":"Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC\/MIC is the most predictive pharmacokinetic\/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother. 2010;65(9):1984\u201390. https:\/\/doi.org\/10.1093\/jac\/dkq226.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"4522_CR27","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/jac\/dku561","volume":"70","author":"MH Rigatto","year":"2015","unstructured":"Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, Costa LW, Zavascki AP. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother. 2015;70(5):1552\u20137. https:\/\/doi.org\/10.1093\/jac\/dku561.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"4522_CR28","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1093\/jac\/dkq285","volume":"65","author":"LS Elias","year":"2010","unstructured":"Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother. 2010;65(10):2231\u20137. https:\/\/doi.org\/10.1093\/jac\/dkq285.","journal-title":"J Antimicrob Chemother"},{"key":"4522_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9080451","author":"Y Cai","year":"2020","unstructured":"Cai Y, Leck H, Tan RW, Teo JQ, Lim TP, Lee W, Chlebicki MP, Kwa AL. Clinical experience with high-dose polymyxin B against carbapenem-resistant gram-negative bacterial infections-a cohort study. Antibiotics. 2020. https:\/\/doi.org\/10.3390\/antibiotics9080451.","journal-title":"Antibiotics"},{"issue":"11","key":"4522_CR30","doi-asserted-by":"publisher","first-page":"7000","DOI":"10.1128\/AAC.00844-15","volume":"59","author":"BC Nelson","year":"2015","unstructured":"Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, Jenkins SG, Whittier S, Calfee DP, Furuya EY, Kubin CJ. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother. 2015;59(11):7000\u20136. https:\/\/doi.org\/10.1128\/AAC.00844-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"4522_CR31","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.2147\/DDDT.S313714","volume":"15","author":"X Wu","year":"2021","unstructured":"Wu X, Huang C, Wang H, Ji J, Ying C, Xiao Y. Optimal empiric polymyxin B treatment of patients infected with gram-negative organisms detected using a blood antimicrobial surveillance network in China. Drug Des Devel Ther. 2021;15:2593\u2013603. https:\/\/doi.org\/10.2147\/DDDT.S313714.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"4522_CR32","doi-asserted-by":"publisher","first-page":"2200131","DOI":"10.1056\/EVIDoa2200131","volume":"2","author":"S Kaye Keith","year":"2022","unstructured":"Kaye Keith S, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu C-H, Daikos G, Dhar S, Durante-Mangoni E, Gikas A, Kotanidou A, et al. Colistin monotherapy versus combination therapy for carbapenem-resistant organisms. NEJM Evidence. 2022;2(1):2200131. https:\/\/doi.org\/10.1056\/EVIDoa2200131.","journal-title":"NEJM Evidence"},{"key":"4522_CR33","doi-asserted-by":"publisher","first-page":"620885","DOI":"10.3389\/fmed.2021.620885","volume":"8","author":"Q Lu","year":"2021","unstructured":"Lu Q, Zhu HH, Li GH, Qi TT, Ye LJ, Teng XQ, Qu Q, He GF, Qu J. A comparative study of the microbiological efficacy of polymyxin B on different carbapenem-resistant gram-negative bacteria infections. Front Med. 2021;8:620885. https:\/\/doi.org\/10.3389\/fmed.2021.620885.","journal-title":"Front Med."}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04522-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T05:03:09Z","timestamp":1686632589000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04522-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4522"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04522-6","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Human Research Ethics Committee of The First Affiliated Hospital of Zhengzhou University (2020-KY-0318-001, 01\/26\/2021) and was conducted in accordance with the Declaration of Helsinki and relevant clinical research regulations in China. Written informed consent was obtained from patients or patients\u2019 legally authorized representatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participate"}},{"value":"All authors approved the manuscript for submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors has any conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}